Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
J Nerv Ment Dis ; 205(6): 480-486, 2017 06.
Article in English | MEDLINE | ID: mdl-28141630

ABSTRACT

The underlying mechanism of modified electroconvulsive therapy (MECT) treatment for drug-resistant and catatonic schizophrenia remains unclear. Here, we aim to investigate whether MECT exerts its antipsychotic effects through elevating N-acetylaspartate (NAA) concentration measured by proton magnetic resonance spectroscopy (H-MRS). Multiple-voxel H-MRS was acquired in the bilateral prefrontal cortex (PFC) and thalamus to obtain measures of neurochemistry in 32 MECT, 34 atypical antipsychotic-treated schizophrenic patients, and 34 healthy controls. We found that both MECT and atypical antipsychotic treatments showed significant antipsychotic efficacy. MECT and atypical antipsychotic treatments reversed the reduced NAA/creatine ratio (NAA/Cr) in the left PFC and left thalamus in schizophrenic patients compared with healthy controls. Furthermore, the NAA/Cr ratio after treatments was significant higher in the MECT group, but not in the medication group. Our findings demonstrate that eight times of MECT elevated the relative NAA concentration to display neuroprotective effect, which may be the underlying mechanism of rapid antipsychotic efficacy.


Subject(s)
Aspartic Acid/analogs & derivatives , Electroconvulsive Therapy/methods , Neuroprotection/physiology , Outcome Assessment, Health Care , Prefrontal Cortex/metabolism , Schizophrenia/metabolism , Schizophrenia/therapy , Thalamus/metabolism , Adult , Aspartic Acid/metabolism , Creatine/metabolism , Female , Humans , Male , Prefrontal Cortex/diagnostic imaging , Proton Magnetic Resonance Spectroscopy , Schizophrenia/diagnostic imaging , Thalamus/diagnostic imaging , Young Adult
2.
Neuropharmacology ; 52(3): 966-74, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17141281

ABSTRACT

This paper studied the effect of neurosteroid dehydroepiandrosterone sulfate on spontaneous glutamate release in the prelimbic cortex by using electrophysiological and biochemical methods combined with a pharmacological approach and made some comparisons with those in the hippocampus. The results showed that dehydroepiandrosterone sulfate increased the frequency of miniature excitatory postsynaptic currents in the prelimbic cortex and hippocampus; sigma-1 receptor antagonist partially blocked the effect of dehydroepiandrosterone sulfate in the prelimbic cortex, but completely blocked it in the hippocampus; D1 receptor antagonist, adenylyl cyclase inhibitor and protein kinase A inhibitor completely blocked the effect of dehydroepiandrosterone sulfate in the prelimbic cortex; dehydroepiandrosterone sulfate increased the activity of protein kinase A in the prelimbic cortex and hippocampus; the effect of dehydroepiandrosterone sulfate on protein kinase A was completely blocked by sigma-1 receptor antagonist in the hippocampus, but was partially blocked in the prelimbic cortex; interestingly, here again, the effect of dehydroepiandrosterone sulfate on protein kinase A was completely blocked by D1 receptor antagonist in the prelimbic cortex. These results suggest that dehydroepiandrosterone sulfate promotes presynaptic glutamate release in the prelimbic cortex via activation of D1 and sigma-1 receptors.


Subject(s)
Cerebral Cortex/drug effects , Dehydroepiandrosterone Sulfate/pharmacology , Glutamic Acid/metabolism , Receptors, Dopamine D1/metabolism , Receptors, sigma/metabolism , Animals , Animals, Newborn , Benzazepines/pharmacology , Cerebral Cortex/cytology , Cyclic AMP-Dependent Protein Kinases/metabolism , Dopamine Antagonists/pharmacology , Dose-Response Relationship, Drug , Drug Interactions , Enzyme Inhibitors/pharmacology , Excitatory Postsynaptic Potentials/drug effects , Excitatory Postsynaptic Potentials/physiology , Excitatory Postsynaptic Potentials/radiation effects , Hippocampus/drug effects , Hippocampus/physiology , Imines/pharmacology , In Vitro Techniques , Membrane Potentials/drug effects , Membrane Potentials/physiology , Patch-Clamp Techniques/methods , Pyrimidines/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, sigma/antagonists & inhibitors , Synaptosomes/drug effects , Synaptosomes/metabolism , Sigma-1 Receptor
3.
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue ; 17(3): 180-2, 2005 Mar.
Article in Zh | MEDLINE | ID: mdl-15760536

ABSTRACT

OBJECTIVE: To study the influence of beginning time of cranial hypothermia treatment on the prognosis of extensive cerebral infarction(ECI) so as to establish the optimum time for such treatment. METHODS: Ninety-two ECI patients were divided into three groups. In group A hypothermia treatment was begun within 6 hours after cerebral infarction in 31 patients. In another 31 cases in group B it was begun in 7-10 hours, and in 30 cases in group C it was begun in 11-14 hours after the attack. The mortality rate, the volume of cerebral infarction, neurological deficiency score(NDS) and quality of life in survivors were determined respectively in three groups. RESULTS: The volume of cerebral infarction in group A and B was obviously smaller than that of group C after hypothermia treatment(P<0.01). The mortality rate was higher in group C (26.67% in group C, 3.23% in group A and 6.45% in group B, both P<0.05) The mortality rate was highest in cases with high body temperature in group C(P<0.05). NDS was significantly lower in survivors of groups A and B compared with group C (both P<0.05), groups A and B compared with group C(P<0.05). The NDS and quality of life of the survivors with high body temperature(P<0.05 or P<0.01). CONCLUSION: Cranial hypothermia treatment should be begun with 10 hours after illness to obtain best effect.


Subject(s)
Cerebral Infarction/therapy , Hypothermia, Induced , Humans , Prognosis , Time Factors
4.
Behav Brain Res ; 283: 78-86, 2015 Apr 15.
Article in English | MEDLINE | ID: mdl-25619684

ABSTRACT

Hippocampal pathology has been considered to underlie clinical, functional and cognitive impairments in schizophrenia. While longitudinal magnetic resonance imaging (MRI) studies have demonstrated progressive gray matter reduction of the hippocampus during the early phases of schizophrenia (SCZ), very little is known about whether functional connectivity (FC) between the hippocampus and other brain regions also exhibit progressive changes. In this study, resting state functional MRI (fMRI) was used to examine changes in hippocampal connectivity at baseline and follow-up scans comparing 68 patients with first episode SCZ and 62 matched controls. At baseline and follow-up, in the bilateral hippocampal network, SCZ mainly showed decreased FC with bilateral cerebellum posterior lobe, frontal gyrus temporal gyrus, precuneus, and cingulate cortex compared to controls. Furthermore, in the bilateral hippocampus, there was a significant interaction effect of group and time for FC with cerebellum posterior lobe, temporal gyrus, frontal gyrus, and posterior cingulate cortex. Interestingly, longitudinal changes of bilateral hippocampal connectivity with right middle frontal gyrus negatively correlated with positive symptom scores in SCZ. These results provide novel evidence for the progressive changes of FC between hippocampus and other brain regions in SCZ. It further suggests that longitudinal changes of bilateral hippocampal connectivity with right middle frontal gyrus can contribute to the formation and emergence of positive symptom of SCZ.


Subject(s)
Hippocampus/physiopathology , Schizophrenia/physiopathology , Adult , Brain Mapping , Disease Progression , Female , Follow-Up Studies , Humans , Longitudinal Studies , Magnetic Resonance Imaging , Male , Neural Pathways/physiopathology , Psychiatric Status Rating Scales , Rest
5.
Psychiatry Res ; 223(1): 23-7, 2014 Jul 30.
Article in English | MEDLINE | ID: mdl-24831926

ABSTRACT

Early onset schizophrenia (EOS) is often associated with poorer outcomes, including lack of school education, higher risk of mental disability and resistance to treatment. But the knowledge of the neurobiological mechanism of EOS is limited. Here, using proton magnetic resonance spectroscopy, we investigated the possible neurochemical abnormalities in prefrontal cortex (PFC) and thalamus of first-episode drug-naïve patients with EOS, and followed up the effects of atypical antipsychotic treatment for 6 months on neurochemical metabolites and clinical symptoms. We measured the ratios of N-acetylaspartate (NAA), choline (Cho) to creatine (Cr) in 41 adolescents with first episode of EOS and in 28 healthy controls matched for age, gender, and years of education. The EOS patients presented with abnormally low NAA/Cr values in the left PFC and left thalamus with a reduced tendency in the right PFC compared with healthy controls. No significant differences were detected between groups for Cho/Cr in PFC and thalamus in any hemisphere. After atypical antipsychotic treatment for 6 months, the reduced NAA/Cr in the left PFC and left thalamus in EOS patients was elevated to the normal level in healthy controls, without any alteration in Cho/Cr. We also found that there was no significant correlation between the neurochemical metabolite ratios in the PFC and thalamus in patients with EOS, and clinical characteristics. Our results suggest that there was neurochemical metabolite abnormalities in PFC and thalamus in EOS patients, atypical antipsychotic treatment can effectively relieve the symptoms and restore the reduced NAA in PFC and thalamus.


Subject(s)
Antipsychotic Agents/therapeutic use , Aspartic Acid/analogs & derivatives , Magnetic Resonance Spectroscopy/methods , Prefrontal Cortex/drug effects , Schizophrenia/drug therapy , Thalamus/drug effects , Adolescent , Adult , Age of Onset , Aspartic Acid/metabolism , Case-Control Studies , Choline/analysis , Choline/metabolism , Creatine/analysis , Creatine/metabolism , Female , Humans , Magnetic Resonance Imaging , Male , Prefrontal Cortex/metabolism , Prefrontal Cortex/pathology , Protons , Schizophrenia/metabolism , Schizophrenia/pathology , Thalamus/metabolism , Thalamus/pathology , Treatment Outcome , Young Adult
6.
Exp Neurol ; 210(1): 128-36, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18035354

ABSTRACT

Dehydroepiandrosterone sulphate is one of the most important neurosteroids. In the present paper, we studied the effect of dehydroepiandrosterone sulphate on persistent sodium currents and its mechanism and functional consequence with whole-cell patch clamp recording method combined with a pharmacological approach in the rat medial prefrontal cortex slices. The results showed that dehydroepiandrosterone sulphate inhibited the amplitude of persistent sodium currents and the inhibitory effect was significant at 0.1 microM, reached maximum at 1 microM and decreased with the increase in the concentrations of above 1 microM. The effect of dehydroepiandrosterone sulphate on persistent sodium currents was canceled by the Gi protein inhibitor and the protein kinase C inhibitor, but not by the protein kinase A inhibitor. The effect of dehydroepiandrosterone sulphate on persistent sodium currents was also canceled by the sigma-1 receptor blockers and the sigma-1 receptor agonist could mimic the effect of dehydroepiandrosterone sulphate. Dehydroepiandrosterone sulphate had no significant influence on neuronal excitability but could significantly inhibit chemical inhibition of mitochondria-evoked increase in persistent sodium currents. These results suggest that dehydroepiandrosterone sulphate inhibits persistent sodium currents via the activation of sigma-1 receptors-Gi protein-protein kinase C-coupled signaling pathway, and the main functional consequence of this effect of DHEAS is presumably to protect neurons under ischemia.


Subject(s)
Dehydroepiandrosterone Sulfate/pharmacology , Membrane Potentials/drug effects , Prefrontal Cortex/drug effects , Receptors, sigma/metabolism , Sodium Channels/physiology , Analysis of Variance , Animals , Animals, Newborn , Dose-Response Relationship, Drug , Drug Interactions , Enzyme Inhibitors/pharmacology , In Vitro Techniques , Neural Inhibition/drug effects , Neurons/drug effects , Patch-Clamp Techniques/methods , Phenylacetates/pharmacology , Prefrontal Cortex/cytology , Pyrrolidines/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, sigma/antagonists & inhibitors , Sigma-1 Receptor
7.
Int J Neuropsychopharmacol ; 11(5): 611-24, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18184443

ABSTRACT

Pregnenolone sulphate (PREGS) is one of the most important neuroactive steroids. Previous study showed that PREGS enhanced long-term potentiation (LTP) via activation of post-synaptic NMDA receptors at excitatory synapses in the hippocampus. The present paper studied the effect of PREGS on LTP at excitatory synapses in the pyramidal cells of layers V-VI of the medial prefrontal cortex (mPFC) using whole-cell patch-clamp in slices and made a comparison with that in the hippocampus. We also studied the mechanism of the effect of PREGS in the mPFC. We found that PREGS inhibited induction of LTP in the mPFC and had no influence on NMDA currents, which was different from its effect in the hippocampus. Moreover, the effect of PREGS on LTP in the mPFC was cancelled by alpha2-adrenoreceptor antagonist, alpha2A-adrenoreceptor antagonist, Gi protein inhibitor, adenylate cyclase inhibitor and protein kinase A inhibitor. These results suggest that PREGS inhibits LTP via activation of the alpha2-adrenoreceptor-Gi protein-adenylate cyclase-protein kinase A signalling pathway in the mPFC.


Subject(s)
Long-Term Potentiation/drug effects , Prefrontal Cortex/cytology , Pregnenolone/pharmacology , Pyramidal Cells/drug effects , Receptors, Adrenergic, alpha-2/physiology , Synapses/drug effects , Adenylyl Cyclases/pharmacology , Adrenergic alpha-Antagonists/pharmacology , Animals , Animals, Newborn , Dose-Response Relationship, Drug , Dose-Response Relationship, Radiation , Drug Interactions , Electric Stimulation/methods , Enzyme Inhibitors/pharmacology , Excitatory Postsynaptic Potentials/drug effects , Excitatory Postsynaptic Potentials/physiology , Excitatory Postsynaptic Potentials/radiation effects , In Vitro Techniques , Long-Term Potentiation/physiology , Long-Term Potentiation/radiation effects , N-Methylaspartate/pharmacology , Rats , Rats, Sprague-Dawley
SELECTION OF CITATIONS
SEARCH DETAIL